[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transthyretin-mediated-amyloidosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transthyretin-mediated-amyloidosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100405602","conttribute-a-global-observational-study-of-patients-with-transthyretin-ttr-mediated-amyloidosis-attr-amyloidosis-100405602",false,"NCT04561518","ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)","ConTTRibute","Inclusion Criteria:\n\n* Diagnosis of ATTR amyloidosis or documented known disease-causing TTR variant for the cohort of pre-symptomatic carriers\n* Germany Only: Patients must be treated per the summary of product characteristics (SmPC) for any approved treatment for ATTR amyloidosis\n\nExclusion Criteria:\n\n* Current enrollment in a clinical trial for any investigational agent","ALL",{"count":19,"type":20},1500,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to:\n\n* Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients\n* Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting\n* Describe disease emergence\u002Fprogression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant",[24,25],"Transthyretin-Mediated Amyloidosis","ATTR Amyloidosis",[27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46],"RNAi therapeutic","Transthyretin","TTR","Amyloidosis","Hereditary Transthyretin-mediated (hATTR) Amyloidosis","hATTR amyloidosis","Hereditary ATTR amyloidosis","Wild-type amyloidosis","wtATTR amyloidosis","ATTRv amyloidosis","ATTRwt amyloidosis","Polyneuropathy","Familial amyloid polyneuropathies","ATTR","Transthyretin amyloidosis","TTR-mediated amyloidosis","Polyneuropathies","Amyloid neuropathies","Amyloid neuropathies, familial","Amyloidosis, familial","RECRUITING","2026-05-27",{"date":50,"type":51},"2026-05-29","ACTUAL",{"date":53,"type":51},"2020-11-23",{"date":55,"type":20},"2033-12-31",{"name":57,"class":58},"Alnylam Pharmaceuticals","INDUSTRY",40]